|
Market Closed -
Nasdaq
01:30:00 26/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 8.590 USD | +0.82% |
|
-1.04% | +10.13% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,195 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 33.66% | - | - |
| Enterprise Value (EV) | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,195 | 2,195 | 2,195 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 33.66% | 0% | 0% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.74x | 12.9x | 10.3x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.03x | -188x | 4.66x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.4x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.13x | 2.98x | 2.63x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.13x | 2.98x | 2.63x |
| EV / EBITDA | -0x | -0x | -0x | -0x | 0x | -4.41x | 10.7x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -4.32x | 8.88x | 6.96x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -35.5x | 7.97x | 5.52x |
| FCF Yield | -5.8% | -7.63% | -7.93% | -3.41% | 21% | -2.82% | 12.5% | 18.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.296 | 0.6647 | 0.8307 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 702.2 | 737.3 | 833.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -497.8 | 204.5 | - |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 315.5 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -578.8 | 184.4 | 250 |
| Net Debt | -368.3 | - | 426.7 | 507.7 | - | - | - | - |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 8.590 | 8.590 | 8.590 |
| Nbr of stocks (in thousands) | 1,79,936 | 1,86,424 | 2,04,809 | 2,07,133 | 2,10,543 | 2,55,535 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 26/02/24 | 24/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.71x | - | - | -.--% | 219.5Cr | |
| 21.09x | 7.5x | 15.07x | 1.41% | 7.23TCr | |
| 30.84x | 8.88x | 27.67x | 0.04% | 6.02TCr | |
| 31.46x | 6.7x | 17.4x | -.--% | 2.77TCr | |
| -74.58x | 14.32x | -78x | -.--% | 2.57TCr | |
| -15.17x | 5.73x | -7.2x | -.--% | 2.47TCr | |
| 28.35x | 5.34x | 17.75x | -.--% | 2.07TCr | |
| 42.74x | 15.97x | 32.4x | 0.35% | 1.51TCr | |
| 17.9x | 5.33x | 12.45x | -.--% | 1.44TCr | |
| 1013.62x | 35.48x | 612.89x | -.--% | 1.42TCr | |
| Average | 109.25x | 11.70x | 72.27x | 0.18% | 2.77TCr | |
| Weighted average by Cap. | 64.41x | 9.84x | 39.28x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
